Dr. Reddy's Laboratories Limited (RDY) Stock: Price, Forecast & Analyst Target
Dr. Reddy's Laboratories Limited (RDY) — MoonshotScore 77/100 (Strong band), calculated Nov 18, 2026. Price $14.85 (-0.90%), as of the Nov 19, 2026 trading session; market cap $12.4B. Expected results Jan 22, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Dr. Reddy's Laboratories Limited · RDY · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Dr. Reddy's Laboratories (RDY)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and a strong balance sheet, but a full valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Sound; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue ₹86.59B (Q2 FY2027, quarter ended Sep 2026)
- EPS beat 5 of the last 8 reports
- Altman Z 5.67 · Piotroski F 5
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 84 | Exceptional | |
| 84 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional | |
| 77 | Strong | |
| 77 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $14.85 | |
| Change on the day | -0.90% | |
| 52-week range | $11.36–$15.67 | |
| Market capitalisation | $12.4B | — |
| Price / earnings (trailing) | 41.15 | |
| Shares traded on the day | 1.59M | |
| Beta (volatility vs the S&P 500) | 0.25 | |
| Dividends per share (last 12 months) | $0.08 | |
| Dividend yield (last 12 months) | 0.56% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · in line with the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
So we believe that is already part of the gross margins, and then we believe, I think, this trend will continue for Q3 and Q4 as well.
Mannam Venkatanarasimham · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Dr. Reddy's Laboratories (RDY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 16, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Dr. Reddy's Laboratories (RDY), and what does it report?
Short answer
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. Dr. Reddy's Laboratories Limited (RDY) is listed on NYSE. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: 8-2-337, Road NO.3 Banjara Hills, Hyderabad, 500-034. It employs 27,527 people and is led by Erez Israeli. In Q2 FY2027 it reported revenue of ₹86.59B and net income of ₹9.24B. The market values it at $12.4B.
What do the latest results show for Dr. Reddy's Laboratories (RDY)?
Short answer · as of
The most recent reported quarter, Q2 FY2027, carried revenue of ₹86.59B. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $910.89M Oct 23, 2026
- Latest report · revenue estimate
- $894.94M Oct 23, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 23, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 23, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 23, 2026 | $910.89M | $894.94M | $0.1200 | $0.0968 |
| Jul 21, 2026 | $835.68M | $850.56M | $0.0600 | $0.0918 |
| May 11, 2026 | $785.89M | $886.57M | $0.0600 | $0.0900 |
| Jan 20, 2026 | $951.64M | $927.68M | $0.1600 | $0.1600 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2027 | ₹86.59B | ₹9.24B | ₹11.09 (diluted) |
| Q1 FY2027 | ₹81.18B | ₹4.46B | ₹5.36 (diluted) |
| Q4 FY2026 | ₹76.33B | ₹2.24B | ₹2.68 (diluted) |
| Q3 FY2026 | ₹87.27B | ₹12.10B | ₹14.52 (diluted) |
What are the financial strengths and risks for Dr. Reddy's Laboratories (RDY)?
Short answer · as of
The MoonshotScore pillars rate business quality, balance-sheet strength, positive momentum as strengths. The distress and quality screens read Altman Z 5.67 · Piotroski F 5. Trailing ratios: ROE 7.4% · ROA 4.9% · current ratio 1.93 · earnings yield 2.4% · free-cash-flow yield 1.0%.
What should you watch next at Dr. Reddy's Laboratories (RDY)?
Short answer · as of
The next earnings report is expected on Jan 22, 2027. Current published price targets run low $13.90 · high $14.80 · consensus $14.35 · median $14.35 against a quoted price of $14.85 (as of Nov 19, 2026).
What management is planning
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Dr. Reddy's Laboratories compare with its peers?
Short answer
Dr. Reddy's Laboratories's score ranks 6th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $102.00 Nov 18, 2026 | $6.67B | 96 5-pillar Nov 18, 2026 | |
| $71.47 Nov 18, 2026 | $1.62B | 94 5-pillar Nov 18, 2026 | |
| $36.48 Nov 19, 2026 | $1.46B | 92 5-pillar Nov 18, 2026 | |
| $85.57 Nov 18, 2026 | $34.8B | 87 5-pillar Nov 18, 2026 | |
| $35.57 Nov 18, 2026 | $1.44B | 78 5-pillar Nov 18, 2026 | |
| Dr. Reddy's Laboratories (RDY) — this page | $14.85 | $12.4B | 77 |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $28.96 Nov 18, 2026 | $6.02B | 74 5-pillar Nov 18, 2026 | |
| $21.27 Nov 18, 2026 | $68.0B | 73 5-pillar Nov 18, 2026 | |
| $13.99 Nov 18, 2026 | $2.43B | 70 5-pillar Nov 18, 2026 | |
| $21.88 Nov 18, 2026 | $7.62B | 66 5-pillar Nov 18, 2026 | |
| $42.23 Nov 18, 2026 | $49.3B | 57 5-pillar Nov 18, 2026 | |
| $4.69 Nov 18, 2026 | $2.33B | 47 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $13.90 – $14.80
- Consensus target
- $14.35
- Median target
- $14.35
Consensus record · Captured .
Measured against a quoted price of $14.85 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 15.4% Period end Sep 30, 2026
- Previous quarter · ownership
- 15.1% Prior to period end Sep 30, 2026
- Reporting holders
- 233 Period end Sep 30, 2026
- Previous quarter · holders
- 242 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Morgan Stanley | 24,293,913 |
| Blackrock, INC. | 9,169,667 |
| Aikya Investment Management Ltd | 9,068,536 |
| Royal Bank Of Canada | 8,692,737 |
| Robeco Institutional Asset Management B.V. | 8,680,810 |
Tracked investors
Which of the 16 named investors we follow held RDY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RDY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Dr. Reddy's Laboratories (RDY)?
- Dr. Reddy's Laboratories Receives VAI Classification from USFDA
- Tonix Pharmaceuticals Files Patent Infringement Complaint Against Dr. Reddy's Laboratories On Nov 13, 2026; Seeks To Delay FDA Approval Of Dr. Reddy’s Laboratories Anda Until Patent Expiration; Triggers Statutory Stay Of FDA Approval Of Dr. Reddy’s Laboratories ANDA For Up To 30 Months
What Investors Ask About Dr. Reddy's Laboratories (RDY) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
What does Dr. Reddy’s Global Generics business sell?
Global Generics sells prescription and over-the-counter finished medicines under proprietary brands or as generic equivalents, and it also contains the biologics activity. Its revenue reflects commercial medicine sales rather than ingredient supply or contract research work.
How does Dr. Reddy’s PSAI business differ from Global Generics?
PSAI supplies active ingredients, chemical intermediates, custom ingredients and steroids, while also providing contract research. Global Generics sells finished medicines and biologics, so the divisions serve different stages of pharmaceutical production.
What does the Curis partnership add to Dr. Reddy’s oncology work?
The Curis partnership extends Dr. Reddy’s activity into the discovery, development and commercialization of small-molecule antagonists aimed at immuno-oncology and precision-oncology targets. It sits alongside the company’s broader development work in cancer and inflammatory conditions.
What is the RDY stock price today?
The last price recorded for Dr. Reddy's Laboratories Limited (RDY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RDY price target?
The analyst consensus price target for Dr. Reddy's Laboratories Limited (RDY), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does RDY pay a dividend?
Yes. The dividend yield of Dr. Reddy's Laboratories Limited (RDY) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 56 figures on this page — 2 from SEC filings and earnings calls, 44 from Financial Modeling Prep (FMP), 4 with no recorded source, 4 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com